Low affinity of the receptor for 1α, 25-dihydroxyvitamin D3 in the marmoset, a new world monkey  by Liberman, Uri A. et al.
Volume 182, number 2 FEBS 2382 March 1985 
Low affinity of the receptor for la,2Sdihydroxyvitamin D, 
in the marmoset, a New World monkey 
Uri A. Liberman, Donald de Grange and Stephen J. Marx* 
Metabolic Diseases Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, Bethesda, 
MD 20205, USA 
Received 14 January 1985; revised version received 18 January 1985 
Circulating levels of 1,25dihydroxyvitamin D are IO-fold higher in the marmoset, a New World monkey, 
than in man; to assess hormone receptors, we evaluated interactions of 1,25_dihydroxyvitamin D, with vi- 
rus-transformed lympocytes. Soluble extracts of transformed lymphocytes from humans showed hormone 
binding with afftnity and capacity similar to that of receptors for 1,25_dihydroxyvitamin D from other hu- 
man tissues. However, soluble extracts of transformed lymphocytes from the marmoset showed a strikingly 
lower affinity for 1,25_dihydroxyvitamin D (Kd 2.2 vs 0.27 nM in marmoset vs human) and a mildly lower 
binding capacity (6.9 vs 16 fmol/mg protein). A defective receptor for 1,25_dihydroxyvitamin D, could ac- 
count for resistance of target issues to this hormone in the marmoset. 
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1. INTRODUCTION 
1,2%Dihydroxyvitamin D3 (1,25(OH)~D3) is a 
seco-steroid hormone that acts in many tissues; its 
predominant effect at physiologic concentrations 
is an increased transport of calcium from the in- 
testinal lumen to plasma. Shinki et al. [l] reported 
recently that serum concentrations of 1,25(OH)zD3 
in the marmoset (Callithrixjacchus) were extreme- 
ly high but there was no hypercalcemia. This find- 
ing was confirmed by Adams et al. [2] in another 
marmoset (Suguinus imperutor). Despite these 
high levels, marmosets in both studies showed 
signs of calcium deficiency with osteomalacia. We 
have examined 1,25(OH)zD receptors in marmoset 
lymphocytes, transformed by the Epstein-Barr 
virus, and we now report a marked decrease in af- 
finity of soluble cell extracts for 1,25(OH)zD3. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Transformed lymphocytes were generously pro- 
vided by Drs Simeon Taylor, David Brandon and 
George Chrousos. Strains of marmoset (S. 
Oedipus) B95-8 lymphocytes transformed by 
Epstein-Barr virus were originally obtained from 
Life Sciences, St. Petersburg, FL. Human lym- 
phocytes were transformed with Epstein-Barr virus 
by the method of Taylor et al. [3]. The 
MA-250-HVP strain of stump-tailed macaque 
(Macaca arctoides) B-lymphocytes transformed by 
Herpesvirus papio was obtained originally from H. 
Rabin (Frederick Cancer Research Center, 
Frederick, MD). Cells were grown as suspensions 
in medium A (RPM1 1640 with fetal calf serum 
(lo%), glutamine (5.8 pg/ml), and gentamycin 
(lo pg/ml)). 
2.2. Chemicals 
1,25(OH)~D3 was the gift of Dr M. Uskokovic 
(Hoffman La Roche, Nutley, NJ). 1,25[23,24(n)- 
‘H](OH)2D3 (158 Ci/mmol) was purchased from 
Amersham, Arlington Heights, IL. Other 
chemicals were from sources reported previously 
[41. 
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2.3. Preparation of soluble extract from cells 3. RESULTS 
All procedures were performed at 0-4°C. Cells 
(approx. 3 x 10’ cells per experiment) were 
suspended in 100 ml medium A. Medium protein 
was removed by resuspension in medium A 
without fetal calf serum at 48 and 24 h prior to 
harvesting; at time of harvesting they were washed 
in phosphate-buffered saline. Prior to sonication, 
the cells were resuspended in medium B (10 mM 
Tris-HCl, pH 7.4, 300 mM KCl, 10 mM sodium 
molybdate, 1.5 mM EDTA, 1.0 mM dithiothrei- 
tol, and aprotinin (500 Kallikrein Inactivator 
Units/ml)) at a cell concentration of lO*/ml. The 
cell suspension was sonicated with three 5-s bursts 
from a Heat Systems W-375 sonicator in con- 
tinuous mode. The sonicate was then centrifuged 
at 100000 x g for 60 min. The supernate will be 
referred to as soluble extract. 
We evaluated the binding parameters for the in- 
teractions of [3H]1,25(OH)2D3 with soluble ex- 
tracts from transformed lymphocytes of 3 species 
(table 1). The average Kd (0.26 nM) and binding 
capacity (15 fmol/mg protein) with extract from 
transformed human-lymphocytes are comparable 
to values previously obtained for cultured dermal 
fibroblasts from humans (0.13 nM and 
35 fmol/mg) [4]. 
2.4. Binding of [3H]1,25(OH,hDj to soluble 
extracts from cells 
Freshly prepared soluble extract was incubated 
with varying concentrations of [3H] 1,25(OH)zD3 
(1 x 10-10-40 x lo-” M) in a final volume of 
0.2 ml at 4°C for 15 h. Low-affinity binding was 
assessed by coincubation with 1 PM 1,25(OH)zD3. 
Bound radioligand was separated from unbound 
with hydroxyapatite as in [4]. 
With transformed lymphocytes, the mean value 
of 1,25(OH)zD3-binding capacity for marmoset 
was one half that found in cells from normal 
humans. The average affinity for 1,25(OH)zD with 
soluble extract from transformed lymphocytes was 
8-fold lower for marmoset vs human (table 1). 
To assess whether the 1,25(OH)zD3-binding 
features were specific to the B95-8 cell line or to the 
marmoset species, we tested soluble extracts from 
macaque lymphocytes transformed by Herpesvirus 
papio. The binding affinity was similar to that in 
human cell extracts (table 1). While the com- 
parison of receptor properties in B-lymphocytes 
transformed by differing viruses is not ideal, there 
is a strong homology in DNA -sequence and 
2.5. Sucrose density-gradient en trifugation of 
Table 1 
Saturable binding of [3H]1,25(OH)zD3 with soluble 
extract from virus-transformed B-lymphocytes 
radioligand bound to soluble extract 
Soluble extract was prepared and incubated with 
t3Hl 1,25(OH)zD3 with or without 1 PM 
1,25(OH)~D3 as indicated above. To remove un- 
bound [3H] 1,25(OH)zD3, the soluble extract 
associated with [3H] 1,25(OH)zD3 was treated with 
dextran-coated charcoal as described [4]. The 
supernate was layered onto 5-20% sucrose gra- 
dients in medium B without aprotinin. This was 
centrifuged for 17 h at 4°C at 120000 x g in a 
Beckman L-8 centrifuge with an SW-65 rotor. 
Four drop fractions were collected from the bot- 
tom of the gradient, added to 5 ml Aquasol, and 
assayed for 3H. 
Donor species 
Protein was determined by the method of Lowry 
et al. [5]. High-affinity binding was analyzed by 
the method of Scatchard [6]. The criterion for 
saturable binding was a regression analysis of 
bound-over-free ratio vs bound, consistent with a 
single class of binding sites (i.e., the slope differed 
from zero at the 95% level). 
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Human 0.18 18 
Human 0.21 13 
Human 0.08 13 
Human 0.62 20 
Human 0.25 13 
Macaque 0.40 14 
Marmoset 1.2 3.9 
Marmoset 3.9 9.2 
Marmoset 1.5 7.7 
a The mean value for affinity (normalized by 
logarithmic transformation) and the mean value for 
capacity differed in the human vs in marmoset (p < 
0.05 by Duncan’s multiple range test) 
The data refer to cells from 3 normal humans and one 
normal macaque (analyzed l-3 times each) and from 
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biological action of Epstein-Barr virus and shows properties similar to the receptor in many 
Herpesvirus papio [7]. human tissues. 
To characterize further the 1,25(OH)zD~bind- 
ing molecules from the marmoset, we analyzed the 
sedimentation of bound radioligand in sucrose 
density gradients. The radioligand associated with 
extract from transformed lymphocytes of the mar- 
moset showed a sedimentation velocity of approx. 
3.5 S similar to that with extract from human 
transformed lymphocytes (fig.1). The difference in 
amplitudes of the peaks (fig.1) is attributable to a 
higher binding capacity in extract from human 
cells and to less complete binding saturation (at 
4 nM [3H]1,25(OH)2D3) with soluble extract from 
marmoset lymphocytes. 
The 1,25(OH)zD3-binding properties of soluble 
extract from transformed lymphocytes derived 
from the marmoset were different from those of 
human cells. While the capacity of saturable bind- 
ing sites differed only moderately from that of 
human cells, the binding affinity was strikingly 
decreased. The g-fold difference in binding affinity 
correlates well with the fact that circulating levels 
of 1,25(OH)zD are IO-fold higher in the marmoset 
than in man. Thus, a difference in receptor proper- 
ties may explain the unusual features of mineral 
metabolism in the marmoset. 
4. DISCUSSION 
Receptors for 1,25(OH)zD have been identified 
in many tissues; indistinguishable receptors have 
been identified in activated B lymphocytes [8]. We 
have confirmed that the receptor in Epstein-Barr 
virus transformed B-lymphocytes from the human 
Adams reported a 75-85% decrease in 
1,25(OH)zDJ-binding capacity with intact cultured 
dermal fibroblasts from the marmoset (S. im- 
perator) as compared to the human, somewhat 
more abnormal than the 57% decrease in binding 
capacity that we observed with transformed lym- 
phocytes. They did not find abnormal binding af- 
finity with marmoset cells [2]. There is precedent 
for discrepancies among abnormal hormone- 
binding parameters when studied in assays using 
differing cell types or cell fractions. In comparing 
New vs Old World monkeys, greater differences in 
glucocorticoid affinity and capacity were seen with 
soluble extract from virus transformed B- 
lymphocytes than with intact cells [9]. Further 
studies will be required to determine whether the 
receptors in intact vs disrupted transformed cells 
and in intact nontransformed cells of the mar- 
moset are comparable. 
I---- Normal Marmoset 
FRACTION 
Fig. 1. Sedimentation of radioligand in sucrose gradient 
after incubation (at 4.0 nM [3H]1,25(OH)2D3) with 
soluble extract from transformed lymphocytes of human 
and of marmoset. Solid symbols represent soluble 
extract incubated with [3H]1,25(OH)2Ds plus 1 pM 
1,25(OH)zD3. Radioactivity is corrected to a cytosol 
sample mass of 1 mg protein applied to the sucrose 
gradient. Arrows mark the position of [14C]ovalbumin 
(3.7 S). 
A receptor with affinity for 1,25(OH)zD3 lower 
than that from normal humans has been described 
previously only in two preliminary communica- 
tions dealing with primates. Chandler et al. [lo] 
studied interaction of 1,25(OH)zD3 with LLC- 
MK2 cells derived from renal tissue of the rhesus 
(M. mulata), an Old World monkey. Saturable 
binding of radioligand was undetectable, but 
1,25(OH)zD3 induced 25(OH)D 24-hydroxylase n- 
zyme in a manner suggesting mediation by a recep- 
tor with affinity 30-fold lower than in human cells. 
Our finding of normal affinity for 1,25(OH)zD in 
extracts from stump-tailed macaque (M. arctoides) 
lymphocytes uggests that the LLC-MK2 cells have 
special features not characteristic of most cells 
from Old World monkeys. Castells et al. [l l] 
described a child with hereditary resistance to 
387 
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1,25(0H)~D; cultured skin fibroblasts from that 
child showed a binding affinity for 1,25(OH)~Dj 
20-fold below normal. That child showed a 
calcemic response to high doses of 1,25(OH)zD3, 
suggesting that affinity defects in the receptor for 
1,25(OH)zD could be compensated for in vivo. 
These observations suggest that the marmoset 
might serve as a valid model of hereditary 
resistance to 1,25(OH)zD~ in humans. 
New World monkeys, and the marmoset in par- 
ticular, exhibit high circulating levels of gluco- 
corticoids, mineralocorticoids, progesterone, 
estrogen, and 1,25(OH)~Ds [ 1,2,9,12]. Studies with 
cultured cells from New World monkeys have 
established abnormal interactions with glucocor- 
ticoids [9,12] and 1,25(OH)~Ds. Although types of 
defect (binding affinity vs binding capacity) vary 
with the cell system analyzed, the overall pattern 
suggests that the steroid and seco-steroid hor- 
mones share a similar nuclear mechanism of action 
and that one disturbance during primate evolution 
has influenced the effector systems not only for 
multiple steroid hormones but also for 
1,25(OH)~D3, a seco-steroid hormone. 
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